Centralized Reminder/Recall for Human Papillomavirus Vaccination: Findings From Two States-A Randomized Clinical Trial.
Centralized reminder/recall
Human papillomavirus
Immunization
Reminder/recall
Vaccination
Journal
The Journal of adolescent health : official publication of the Society for Adolescent Medicine
ISSN: 1879-1972
Titre abrégé: J Adolesc Health
Pays: United States
ID NLM: 9102136
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
15
09
2020
revised:
23
02
2021
accepted:
26
02
2021
pubmed:
14
4
2021
medline:
28
10
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
Centralized reminder/recall (C-R/R) using Immunization Information Systems has been effective in increasing childhood immunization rates. Previously, C-R/R using autodialer for human papillomavirus (HPV) vaccine did not raise rates. We assessed C-R/R for HPV vaccine using other modalities and focused on younger adolescents. We conducted a three-arm pragmatic RCT in randomly sampled primary care practices in Colorado (n = 88) and New York (n = 136), proportionate to where adolescents received care. We randomized, within practices, adolescents aged 11-14 years who had not completed the HPV vaccination series to receive C-R/R using different modalities (Colorado: autodialer, mail, or control; New York: autodialer, text, or control). Up to two reminders were sent in intervention arms for each dose needed between 2/2017 and 12/2018. In Colorado, no significant differences were found for series initiation (31.3% control, 31.1% autodial, 31.8% mail), with slight improvement for series completion in the autodialer arm (29.7% control, 31.1% autodialer, p = .04) but not the mail arm (30.9%, p = .06). No significant differences were found in New York for series initiation (24.1% for all arms) or completion (17.1% control, 16.9% autodial, 17.9% text). Adjusted analyses showed higher completion rates for the autodialer arm in Colorado but not for other arms. In Colorado, C-R/R reduced time to series completion by around 2 months. Cost per adolescent was $1.81 for mail; under $.40 for all other modalities. C-R/R has less benefit for raising HPV vaccination rates than other studies have noted for childhood immunizations, although it may quicken series completion at little cost.
Identifiants
pubmed: 33846054
pii: S1054-139X(21)00108-7
doi: 10.1016/j.jadohealth.2021.02.023
pmc: PMC9639215
mid: NIHMS1845369
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02993965', 'NCT03294551']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-587Subventions
Organisme : NCI NIH HHS
ID : R01 CA187707
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
Vaccine. 2018 Aug 6;36(32 Pt B):4904-4909
pubmed: 30037480
Vaccine. 2019 Oct 16;37(44):6601-6608
pubmed: 31562003
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Prev Med Rep. 2020 Dec 29;21:101296
pubmed: 33489724
J Adolesc Health. 2015 May;56(5 Suppl):S40-6
pubmed: 25863554
Acad Pediatr. 2018 Mar;18(2S):S3-S10
pubmed: 29502635
Prev Med. 2018 Nov;116:203-210
pubmed: 30267734
Am J Public Health. 2016 Feb;106(2):273-8
pubmed: 26691123
Acad Pediatr. 2020 Apr;20(3):374-383
pubmed: 31698085
Acad Pediatr. 2018 Mar;18(2S):S23-S27
pubmed: 29502633
CA Cancer J Clin. 2013 Jan;63(1):57-81
pubmed: 23258613
Vaccine. 2017 Aug 16;35(35 Pt B):4554-4560
pubmed: 28736201
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
Acad Pediatr. 2017 Apr;17(3):330-338
pubmed: 27913163
JAMA Pediatr. 2015 Apr;169(4):365-73
pubmed: 25706340
Vaccine. 2020 Aug 27;38(38):6027-6037
pubmed: 32758380
J Adolesc Health. 2015 May;56(5 Suppl):S17-20
pubmed: 25863549
Acad Pediatr. 2018 Nov - Dec;18(8):873-881
pubmed: 30031132
Pediatrics. 2016 Sep;138(3):
pubmed: 27573088
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1109-1116
pubmed: 32817598
Vaccine. 2011 Mar 21;29(14):2537-41
pubmed: 21300094
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-924
pubmed: 30138307
J Adolesc Health. 2015 Jan;56(1):85-90
pubmed: 25438965
J Adolesc Health. 2017 Sep;61(3):288-293
pubmed: 28842066
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
Pediatrics. 2020 May;145(5):
pubmed: 32253263
Pediatrics. 2003 Nov;112(5):1076-82
pubmed: 14595049
Pediatrics. 2013 Jun;131(6):1114-24
pubmed: 23650297
MMWR Morb Mortal Wkly Rep. 2012 Apr 20;61:258-61
pubmed: 22513527
Am J Public Health. 2013 Jun;103(6):1116-23
pubmed: 23237154
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccine. 2019 Jan 21;37(4):595-601
pubmed: 30580838
J Adolesc Health. 2017 Jan;60(1):113-119
pubmed: 27836533
Acad Pediatr. 2013 May-Jun;13(3):204-13
pubmed: 23510607
Pharmacoeconomics. 2005;23(11):1107-22
pubmed: 16277547
Cochrane Database Syst Rev. 2018 Jan 18;1:CD003941
pubmed: 29342498
Pediatrics. 2003 Oct;112(4):958-63
pubmed: 14523192
Health Educ Q. 1984 Spring;11(1):1-47
pubmed: 6392204